vTv Therapeutics, Inc.: June 2019 positive data for TTP399 as an add-on therapy to insulin therapy in a 12 week phase 1/2 trial in patients with T1D. Results from the second part of the Ph2 study expected Q1 2020. Recently announced the first patient has been screened for the Ph2 proof of concept study evaluating the safety and efficacy of azeliragon in patients with mild Alzheimer's disease and Type 2 Diabetes. Data-in hand from two Ph. 2 Diabetes (T2) trials: 1. Glucokinase Activator (TTP399); 2. Oral GLP-1r (TTP273). Recently licensed rights to its PDE4 program to Newsoara Biopharma to further its development in China and other Pacific Rim companies as a potential therapeutic for COPD.
Sector/industry:
Healthcare/Biotechnology
Characteristics:
Based in...
USA
Clinical Stage
Phase III, Phase l or ll
Disease Space
Central Nervous System, Diabetes
Industry
Biotechnology
Listing
Public, USA
Market Cap
<100MM
Therapeutic Modalities
Small Molecule
Website:
Address:
4170 Mendenhall Oaks Parkway
High Point, NC 27265
United States

Send Message to Request Information

Log in to download presentation, request a 1x1 meeting, view additional roadshows, and more.

Stock Market Data

Data is being loaded...
Data is being loaded...
Data is being loaded...
Data is being loaded...
Market Data copyright © 2019 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, RTB=Real-Time BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.